Is Systemic Inflammation Associated With Elevated PSA Serum Levels In Patients Submitted Chronic Hemodialysis?
PSA Level and Systemic Inflammation
Backgroundː whereas that systemic inflammation (SI) affects 40–60% of patients on hemodialysis (HD) is characterized by serum C-reactive protein (CRP) level elevation or proinflammatory interleukin production or both. We evaluated the association between SI and total (tPSA) and free PSA (fPSA) in patients on HD with tPSA <4ng / ml.
Methodsː Sixty patients with chronic kidney disease (CKD) undergoing HD and 20 controls were included. Inclusion criteria were patients aged 18-60 years; tPSA < 4 ng/mL without clinically detectable prostate cancer; and patients undergoing HD for >6 months. Patients were excluded if they had local infections or SI. Hs-CRP was measured using turbidimetry, and tPSA and fPSA levels using immunochemoluminescence. Overall, 27 patients had inflammation (hs-CRP >5 mg/L) and 33 had no inflammation (hs-CRP was ≤5 mg/L). In the control group, hs-CRP was ≤ 1 mg/L.
Resultsː there was no significant difference in mean levels among groups 3 and 4 for age (p=0,058), tPSA (p=0,74) and fPSA (p=0,30). The SI did not promote differences between groups 1, 2 and 4 for the levels of tPSA (0,71 ± 0,18 vs 0,67 ± 0,15 vs 0,67 ± 0,11; p=0,69) and fPSA (0,34 ± 0,01 vs 0,34 ± 0,01 vs 0,35 ± 0,01, p= 0,59) . As well as maintained no correlation with tPSA and fPSA (p>0,05).
Conclusionː The systemic inflammation in hemodialytic patients without clinically detectable cancer (PSA<4ng/ml) is no associated with changes fractions of tPSA and fPSA.
2. Trapé J, Filella X, Alsina-Donadeu M, Juan-Pereira L, Bosch-Ferrer Á, Rigo-Bonnin R, et al. Increased plasma concentrations of tumour markers in the absence of neoplasia. Clin Chem Lab Med. 2011;49(10):1605–20.
3. Akchurin OM, Kaskel F. Update on inflammation in chronic kidney disease. Blood Purif. 2015 Jan 20;39(1-3):84–92.
4. Cannizzo ES, Clement CC, Sahu R, Follo C, Santambrogio L. Oxidative stress, inflamm-aging and immunosenescence. J Proteomics. 2011 Oct 19;74(11):2313–23.
5. Cheung CY, Chan GCW, Chan SK, Ng F, Lam MF, Wong SSH, et al. Cancer Incidence and Mortality in Chronic Dialysis Population: A Multicenter Cohort Study. Am J Nephrol. 2016 Apr 12;43(3):153–9.
6. Lin MY, Kuo MC, Hung CC, Wu WJ, Chen LT, Yu ML, et al. Association of dialysis with the risks of cancers. PLoS One. 2015 Apr 13;10(4):e0122856.
7. Stephan C, Miller K, Jung K. Is there an optimal prostate-specific antigen threshold for prostate biopsy? Expert Rev Anticancer Ther. 2011 Aug;11(8):1215–21.
8. Liu X, Tang J, Fei X, Li QY. Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less. Iran J Public Health. 2015;44(11):1466–72.
9. Choi S-K, Song C, Shim M, Min GE, Park J, Jeong IG, et al. Prevalence of high-grade or insignificant prostate cancer in Korean men with prostate-specific antigen levels of 3.0-4.0 ng/mL. Urology. 2015 Mar;85(3):610–5.
10. KDOQI. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007 Sep;50(3):471–530.
11. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation. 2004 Jun 1;109(21 Suppl 1):II2–10.
12. Kirsch AH, Lyko R, Nilsson L-G, Beck W, Amdahl M, Lechner P, et al. Performance of hemodialysis with novel medium cut-off dialyzers. Nephrol Dial Transplant [Internet]. 2016 Sep 1; Available from: http://dx.doi.org/10.1093/ndt/gfw310
13. Carney EF. Chronic kidney disease. Walking reduces inflammation in predialysis CKD. Nat Rev Nephrol. 2014 Jun;10(6):300.
14. Lippi G, Montagnana M, Guidi GC. Epidemiological association between C-reactive protein and prostate-specific antigen. Cancer. 2009 Mar 1;115(5):1132.
15. McDonald AC, Vira MA, Vidal AC, Gan W, Freedland SJ, Taioli E. Association between systemic inflammatory markers and serum prostate-specific antigen in men without prostatic disease - the 2001-2008 National Health and Nutrition Examination Survey. Prostate. 2014 May;74(5):561–7.
16. García-Sánchez C, Corchuelo-Maillo C, Congregado-Ruiz CB, Ocón-Revuelta EM, Osman-García I, Conde-Sánchez JM, et al. PSA levels in patients on hemodialysis treatment. Arch Esp Urol. 2013 Dec;66(10):939–44.
17. Rodríguez Collar TL, Guzmán Cayado M, Rodríguez Batista R, Zamora González Y. Influencia de la hemodiálisis en los niveles del antígeno prostático específico. Revista Habanera de Ciencias Médicas. 2015;14(6):774–86.
18. Maoujoud O, El Machtani S, Asseraji M, Atbib Y, Zajjari Y, Taoufik A, et al. Serum tumor markers in hemodialysis patients. Int J Artif Organs. 2014 Feb;37(2):126–32.
19. Zhang X, Wang N, Xue Q, Jian G, Gao X. Impact of hemodialysis nd uremia on serum levels a of tumor markers. Journal of Integrative Nephrology and Andrology. 2015;2(1):23.
20. İnci M, Çetinkaya A, Yengil E, Oguzhan N, Ulutaş T, Davarcı M. HEMODİYALİZ HASTALARINDA TOTAL VE SERBEST PSA DÜZEYLERİNİN ARAŞTIRILMASI. Mustafa Kemal Üniversitesi Tıp Dergisi [Internet]. 2011;2(8). Available from: http://dergipark.gov.tr/download/article-file/183585
21. Stephan C. Interchangeability of Measurements of Total and Free Prostate-Specific Antigen in Serum with 5 Frequently Used Assay Combinations: An Update. Clin Chem. 2006;52(1):59–64.
22. Wenten IG, Aryanti P, Khoiruddin K, Hakim AN, Himma NF. Advances in Polysulfone-Based Membranes for Hemodialysis. Journal of Membrane Science and Research. 2016;2(2):78–89.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright policies & self-archiving
We are a RoMEO green journal.
Author's Pre-print: author can archive pre-print (ie pre-refereeing)
Author's Post-print: author can archive post-print (ie final draft post-refereeing)
Publisher's Version/PDF: author can archive publisher's version/PDF
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access and Benefits of Publishing Open Access).
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.
Articles are published Under License of Creative Commons Attribution 4.0 License ©